Maryland-based Osiris Therapeutics announced the creation of a new biosurgery division focused on developing and marketing high-end biological products used in surgical procedures. The company hopes to build on the success of Osteocel, an implantable product launched in 2005. Osteocel generated over $40 million in revenue before being sold in 2008 to Nuvasive for “up to $85 million,” according to a company release.
California-based Eiger BioPharmaceuticals acquired an exclusive license from Stanford University for its hepatitis C virus technology. The technology was discovered in the lab of Stanford scientist and Eiger founder Jeffrey Glenn. Financial terms of the deal were not disclosed.
